ArriVent BioPharma, Inc.
AVBP
$24.10
$1.225.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.75M | -31.21M | -64.39M | -20.63M | -20.56M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.49M | 3.12M | 2.27M | 952.00K | 866.00K |
| Change in Net Operating Assets | -4.54M | 1.96M | -5.89M | 3.53M | 3.35M |
| Cash from Operations | -35.80M | -26.12M | -68.01M | -16.15M | -16.35M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.76M | 13.91M | 36.82M | -192.47M | -- |
| Cash from Investing | -50.76M | 13.91M | 36.82M | -192.47M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 86.17M | 75.42M | 6.81M | 55.00K | 531.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 300.00K | -303.00K | -50.00K | -- | -- |
| Cash from Financing | 86.47M | 75.11M | 6.76M | 55.00K | 531.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -93.00K | 62.90M | -24.43M | -208.56M | -15.81M |